# Exelixis, Inc.  Share Price Target ‘$26.74’, now 31.1% Upside Potential

- Link: https://www.directorstalkinterviews.com/exelixis-inc.share-price-target-26.74-now-31.1-upside-potential/4121142817
- Published: 2024-02-16T10:48:29+00:00
- Author: Charlotte Edwards

**Exelixis, Inc.** which can be found using ticker (EXEL) have now 19 analysts in
total covering the stock. The consensus rating is pointing to ‘buy’. The range between
the high target price and low target price is between $32.00 and $18.00 with the
average share target price sitting at $26.74. (at the time of writing). Given that
the stocks previous close was at $20.39 this would imply there is now a potential
upside of 31.1%. The 50 day moving average now sits at $22.45 and the 200 day moving
average is $21.00. The company has a market cap of 6.24B. The stock price for the
company is currently $20.59 USD

 The potential market cap would be $8,186,930,704 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 31.68, revenue per share of $5.75
and a 3.55% return on assets.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines
and combination regimens at the forefront of cancer care. It has four products, 
including its flagship molecule, cabozantinib, which is an inhibitor of multiple
tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved
as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and
in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for
hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated
thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic
medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor
of MEK approved as part of multiple combination regimens to treat specific forms
of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the
mineralocorticoid receptor (MR) approved the treatment of hypertension.

Share on: